NILANDRON(Nilutamide) is an antiandrogen used to treat prostate cancer. NILANDRON(Nilutamide) is a pure, nonsteroidal anti-androgen which blocks androgen binding to androgen receptors. NILANDRON(Nilutamide) blocks the action of androgens of adrenal and testicular origin. NILANDRON(Nilutamide) is contraindicated in patients with known hypersensitivity to the drug or to any constituents of the drug product and in patients with severe hepatic dysfunction or with severe respiratory insufficiency. NILANDRON(Nilutamide) is also contraindicated in women and children. Patients administered nilutamide should be warned against consuming alcohol because of a possible disulfiramlike reaction. Patients should be advised regarding impairment of light adaptation if they plan to operate a vehicle or machinery.
Refer to NILANDRON(Nilutamide) dosing protocol by which patient is being treated. Adults: Oral: 300 mg, usually 300mg daily for the first 30 days, then 150mg once daily (with or without food) Dosage in myelosuppression: no adjustment required Dosage in renal failure: no adjustment required Dosage in hepatic failure: if transaminase >2-3x upper limit of normal, interrupt treatment.
NILANDRON(Nilutamide) side effects include Dizziness (3%, Hot flushes (14%), Gynecomastia (< 1%), Gastrointestinal Nausea and vomiting (4%), Constipation, Anorexia (1%), Hematologic Anemia (4%), Elevated liver function tests (4%), Hepatitis (<1%),Photophobia (1%), Retarded light-to-dark adaptation (11%), Visual disturbances (27%), Dyspnea, Interstitial pneumonitis (rare), Fatigue, Alcohol intolerance, Hyperglycemia, Asthenia. Retarded light-to-dark adaptation usually improves on treatment, and usually resolves when treatment is discontinued. Patients should be cautioned about driving at night or through tunnels. This effect can be alleviated by the wearing of tinted glasses. Interstitial pneumonitis has been described, with an apparently higher incidence in patients of Asian origin. Treatment of NILANDRON(Nilutamide) should be discontinued if pneumonitis is diagnosed, and the use of steroids should be considered. Patients of Asian origin may also be at a high risk of liver function test abnormalities.